These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 26819308)

  • 41. Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies.
    Duan H; Struble E; Zhong L; Mihalik K; Major M; Zhang P; Feinstone S; Feigelstock D
    Vaccine; 2010 Jun; 28(25):4138-44. PubMed ID: 20433800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection.
    Frumento N; Sinnis-Bourozikas A; Paul HT; Stavrakis G; Zahid MN; Wang S; Ray SC; Flyak AI; Shaw GM; Cox AL; Bailey JR
    Immunity; 2024 Jan; 57(1):40-51.e5. PubMed ID: 38171362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis C virus evasion mechanisms from neutralizing antibodies.
    Lorenzo CD; Angus AGN; Patel AH
    Viruses; 2011 Nov; 3(11):2280-2300. PubMed ID: 22163345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of HCV resistance to broadly neutralizing antibodies.
    Frumento N; Flyak AI; Bailey JR
    Curr Opin Virol; 2021 Oct; 50():23-29. PubMed ID: 34329953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
    Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
    Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutralizing antibody response to hepatitis C virus.
    Wang Y; Keck ZY; Foung SK
    Viruses; 2011 Nov; 3(11):2127-45. PubMed ID: 22163337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development.
    Pierce BG; Felbinger N; Metcalf M; Toth EA; Ofek G; Fuerst TR
    Viruses; 2024 May; 16(5):. PubMed ID: 38793684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A point mutation at Asn-534 that disrupts a conserved N-glycosylation motif of the E2 glycoprotein of hepatitis C virus markedly enhances the sensitivity to antibody neutralization.
    Sasayama M; Shoji I; Adianti M; Jiang DP; Deng L; Saito T; Watanabe H; Kawata S; Aoki C; Hotta H
    J Med Virol; 2012 Feb; 84(2):229-34. PubMed ID: 22170542
    [TBL] [Abstract][Full Text] [Related]  

  • 49. B cell immunodominance in primary hepatitis C virus infection.
    Brasher NA; Eltahla AA; Underwood A; Boo I; Rizzetto S; Walker MR; Rodrigo C; Luciani F; Maher L; Drummer HE; Tedla N; Lloyd AR; Bull RA
    J Hepatol; 2020 Apr; 72(4):670-679. PubMed ID: 31785346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine.
    Keck ML; Wrensch F; Pierce BG; Baumert TF; Foung SKH
    Front Immunol; 2018; 9():1194. PubMed ID: 29904384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.
    Law JL; Chen C; Wong J; Hockman D; Santer DM; Frey SE; Belshe RB; Wakita T; Bukh J; Jones CT; Rice CM; Abrignani S; Tyrrell DL; Houghton M
    PLoS One; 2013; 8(3):e59776. PubMed ID: 23527266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein.
    Diotti RA; Sautto GA; Solforosi L; Mancini N; Clementi M; Burioni R
    New Microbiol; 2012 Oct; 35(4):475-9. PubMed ID: 23109015
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?
    Kinchen VJ; Cox AL; Bailey JR
    Trends Microbiol; 2018 Oct; 26(10):854-864. PubMed ID: 29703495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In Vitro Neutralization Assay Using Cultured Hepatitis C Virus.
    Prentoe J; Bukh J
    Methods Mol Biol; 2019; 1911():433-439. PubMed ID: 30593643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.
    Bartosch B; Bukh J; Meunier JC; Granier C; Engle RE; Blackwelder WC; Emerson SU; Cosset FL; Purcell RH
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14199-204. PubMed ID: 14617769
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
    Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization.
    Weber T; Potthoff J; Bizu S; Labuhn M; Dold L; Schoofs T; Horning M; Ercanoglu MS; Kreer C; Gieselmann L; Vanshylla K; Langhans B; Janicki H; Ströh LJ; Knops E; Nierhoff D; Spengler U; Kaiser R; Bjorkman PJ; Krey T; Bankwitz D; Pfeifer N; Pietschmann T; Flyak AI; Klein F
    Immunity; 2022 Feb; 55(2):341-354.e7. PubMed ID: 34990590
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
    Merat SJ; Bru C; van de Berg D; Molenkamp R; Tarr AW; Koekkoek S; Kootstra NA; Prins M; Ball JK; Bakker AQ; de Jong MD; Spits H; Beaumont T; Schinkel J
    J Hepatol; 2019 Jul; 71(1):14-24. PubMed ID: 30797052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.
    Lavillette D; Morice Y; Germanidis G; Donot P; Soulier A; Pagkalos E; Sakellariou G; Intrator L; Bartosch B; Pawlotsky JM; Cosset FL
    J Virol; 2005 May; 79(10):6023-34. PubMed ID: 15857988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New therapeutic options for HCV infection in the monoclonal antibody era.
    Sautto GA; Diotti RA; Clementi M
    New Microbiol; 2012 Oct; 35(4):387-97. PubMed ID: 23109006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.